Clinical trials: Immune Checkpoint Inhibitor
Immune-related Adverse Event
Hyperpolarized 13C-MRI and Metabolomics for Immune-related Adverse Events
This project investigates immune-related adverse events (irAEs) in cancer patients treated with immune checkpoint inhibitors (ICIs), focusing on metabolic changes.
- Trial name
- DNP_irAE (NCT06243250)
- Testing
- Hyperpolarized 13C-MRI
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Arrhythmia, Long QT Syndrome
AI-powered ECG Analysis for Deadly Arrhythmias and ICI Myocarditis
ELDORA is a non-interventional observational data-science study aiming to develop and validate clinical-grade artificial intelligence tools applied to electrocardiogram (ECG) data.
- Conditions
- Arrhythmia, Long QT Syndrome, Immune Checkpoint Inhibitor-Related Myocarditis
- Trial name
- ELDORA (NCT07644715)
- Where
- France
- Volunteers
- 127,000 people, healthy volunteers welcome
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Melanoma
Feasibility of an Enhanced Symptom Monitoring and Expedited Subspecialty Care Referral Intervention to Improve Side Effect Management for Patients With Melanoma Receiving an Immune Checkpoint Inhibitor
This clinical trial tests the feasibility of patient reported outcomes monitoring with early, rapid immunotherapy toxicity subspecialty care to improve side effect management for patients with melanoma receiving an immune…
- Trial name
- NCT07660666
- Testing
- Electronic Health Record Review, Internet-Based Intervention, Patient Navigation
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- OHSU Knight Cancer Institute
Non Small Cell Lung Cancer
Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC
This study aims to investigate the efficacy and safety of fecal microbiota transplantation (FMT) as a treatment for non-small cell lung cancer (NSCLC) patients whose disease has progressed after immune checkpoint inhibitor (ICI)…
- Trial name
- FMT-LUNG (NCT07432984)
- Testing
- Tislelizumab, Fecal Microbiota Transplant(FMT)
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Se-Hoon Lee
Cancer, Immune System Disorder
Montreal Immune-Related Adverse Events (MIRAE) Study
Immune checkpoint inhibitors (ICI) are among the most promising approaches to fighting cancer. However, a substantial percentage of patients experience off-target adverse effects in the form of mild to severe inflammation in…
- Conditions
- Cancer, Immune System Disorder, Inflammatory Reaction, Autoimmune Diseases
- Trial name
- MIRAE (NCT05139706)
- Where
- Canada
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Melanoma, Cognitive Impairment
Cognitive Function in Melanoma Patients Treated With Adjuvant Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs) are a group of novel immunotherapies that boost the body's own defense against the cancer by improving the immune system's ability to recognize and destroy cancer cells.
- Conditions
- Melanoma, Cognitive Impairment, Fatigue, Sleep
- Trial name
- NCT04565769
- Where
- Denmark
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Triple Negative Breast Cancer, Immune Checkpoint Inhibitor
LAG3 Expression in Triple Negative Breast Cancer
This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.
- Trial name
- NCT06259162
- Testing
- LAG-3 expression / immune checkpoint protein expression
- Where
- South Korea
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Non-small Cell Lung Cancer, Non-small Cell Carcinoma
Combining ICI With SBRT or HypoFrx-RT for ES NSCLC
This study will explore the best dose of radiation to be used when treating stage I-III non-small cell lung cancer (NSCLC) with stereotactic body radiation therapy (SBRT) or hypo-fractionated radiotherapy (HypoFrx-RT) that is…
- Conditions
- Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II
- Trial name
- NCT05451173
- Testing
- Stereotactic body radiotherapy, Hypofractionated radiotherapy, Durvalumab
- Where
- China
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Alexander Chi
Non-small Cell Lung Cancer, Radiotherapy Side Effect
Hypofraction Radiotherapy for Locally Advanced Non-small Cell Lung Cancer
Definitive concurrent chemoradiotherapy followed by durvalumab (Pacific protocol) has been the standard modality for stage III locally advanced non-small cell lung cancer.
- Trial name
- NCT05269485
- Testing
- High-dose hypofractionated radiotherapy, Low-dose hypofractionated radiotherapy
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Anhui Provincial Hospital
Neurological Diseases, Auto Immune Disease
Autoimmune Neurological Diseases and Those Secondary to Immunotherapy: Study of Immunological Mechanisms and Research Into Targets of Immune Attack
The pathophysiology of neurological toxicities secondary to immune checkpoint inhibitors (ICIs) is unknown. Various mechanisms have been proposed: activation of cytotoxic CD8 T cells, autoantibodies via activation of B cells and…
- Trial name
- DINAMIC (NCT07456358)
- Testing
- Lumbar puncture and blood sampling
- Where
- 4 sites in France
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HIV-1 Infection
Clinical Research on the Use of Immune Checkpoint Inhibitors Combined With Chidamide for the Functional Cure of AIDS
Evaluate the efficacy and safety of immune checkpoint inhibitors combined with chidamide as an "activate and kill" strategy to extend viral rebound time, reduce the HIV reservoir, and achieve functional cure.
- Trial name
- NCT06902038
- Testing
- PD-1 inhibitor, Sidarbenamide
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Jun Chen, MD
Large Cell Neuroendocrine Carcinoma of the Lung
Atezolizumab in Large Cell Neuroendocrine Carcinoma
Large-cell neuroendocrine carcinoma (LCNEC) of the lung is a rare and aggressive malignancy with limited prospective evidence to guide systemic treatment.
- Trial name
- LANCE (NCT06049966)
- Testing
- Atezolizumab, Carboplatin, Etoposide
- Where
- 3 sites in Greece
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Oncology Center of Biochemical Education And Research
Stage IV Melanoma, Advanced Lung Cancer
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
The purpose of this study is to refine and pilot test educational material developed to educate and support patients receiving immunotherapy for advanced cancer.
- Conditions
- Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma
- Trial name
- UPLIFT (NCT04670445)
- Testing
- Educational Video and QPL List, Usual Care
- Where
- United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Melanoma, Renal Cancer
Microbiome Immunotherapy Toxicity and Response Evaluation
This is a observational study to investigate how the microbiome correlates with efficacy and toxicity of immune checkpoint inhibitors in patients with advanced cancer.
- Conditions
- Melanoma, Renal Cancer, Lung Cancer
- Trial name
- NCT04107168
- Testing
- Nivolumab, Pembrolizumab, Ipilimumab
- Where
- 13 sites in United Kingdom
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- CCTU- Cancer Theme
Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
Liver Cancer and Immunotherapy in the Liquid Biopsy Era
The goal of this prospective clinical trial is to identify a predictive biomarker in patients with advanced HCC (stage B and C) using a combinatorial approach of the liquid biopsy.
- Conditions
- Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Immune Checkpoint Inhibitor
- Trial name
- LILIPSY (NCT05810402)
- Testing
- Liquid Biopsy
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Gastric Cancer
Real World Study of Immune Checkpoint Inhibitors for Advanced Gastric Cancer
Gastric cancer ranks as the fifth most common and the third most common cause of cancer deaths in the world. In spite of the progresses made in the diagnosis and treatment of gastric cancer in the past decades, the prognosis is…
- Trial name
- NCT04086888
- Where
- 2 sites in China
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
NSCLC Associated With Leptomeningeal Metastases
Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC
This is a prospective, single-arm, open clinical study, which was designed to evaluate the efficacy and safety of an immune checkpoint inhibitor combined with pemetrexed intrathecal injection in the treatment of patients with…
- Trial name
- NCT06132698
- Testing
- Tislelizumab or pembrolizumab, pemetrexed
- Where
- China
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- West China Hospital
Clear-cell Metastatic Renal Cell Carcinoma, Immune Checkpoint Inhibitors
Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
Study Objective: To determine the efficacy of upfront immune checkpoint inhibitors combined with deferred cytoreductive nephrectomy in treating metastatic renal cell carcinoma.
- Conditions
- Clear-cell Metastatic Renal Cell Carcinoma, Immune Checkpoint Inhibitors, Cytoreductive Nephrectomy
- Trial name
- NCT06279403
- Testing
- Toripalimab, Cytoreductive Nephrectomy, Axitinib
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital
Circulating Tumor Cells (CTCs), Immunotherapy
Predicting Clinical Efficacy of Immunotherapy Using Pre-treatment andContinuousMonitoring of PD-L1 TPS/CPS on CTCs, and Immunity Exhaustion Scores
Head and neck cancer is ranked among the fifth to eighth most prevalent cancers worldwide and is associated with a high mortality rate.
- Conditions
- Circulating Tumor Cells (CTCs), Immunotherapy, PD-L1 Expression, Liquidbiopsies
- Trial name
- NCT07396259
- Where
- Taiwan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Melanoma, Non-small Cell Lung Cancer (NSCLC)
Taste and Smell Dysfunction in Patients More Than Two Years After Start of Immune Checkpoint Inhibitor Therapy
Background of the study: Immune checkpoint inhibitors (ICIs) are widely used as treatment for multiple cancer types and the number of patients with longterm disease control after ICIs is increasing.
- Conditions
- Melanoma, Non-small Cell Lung Cancer (NSCLC), Urogenital Cancers
- Trial name
- TasteSPICIER (NCT06495008)
- Testing
- no intervention, only questionnaires, saliva collection and taste/smell tests
- Where
- Netherlands
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen